Last €715.54 EUR
Change Today +1.89 / 0.27%
Volume 0.0
G2A On Other Exchanges
SIX Swiss Ex
As of 3:06 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

galenica ag-reg (G2A) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - €789.85
52 Week Low
09/2/13 - €569.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GALENICA AG-REG (G2A)

Related News

No related news articles were found.

galenica ag-reg (G2A) Related Businessweek News

No Related Businessweek News Found

galenica ag-reg (G2A) Details

Galenica Ltd. develops, manufactures, and markets pharmaceutical products in Switzerland and internationally. Its Pharma segment offers iron replacement products, including Ferinject/Injectafer, Venofer, and Maltofer; immuno-stimulant products, such as Broncho-Vaxom and Uro-Vaxom; infectious diseases/OTX products, over-the-counter products, and herbal remedies; and synthetic and biotech drugs for use in immunology and the treatment of infectious diseases. This segment also provides products for patients suffering from chronic kidney disease; develops and markets CellCept for various applications involving autoimmune diseases; and markets products manufactured by third parties. The company’s Logistics segment offers pre-wholesale logistics services, including storage and distribution of products, and debt collection services to pharmaceutical and healthcare companies; supplies healthcare products to pharmacies, physicians, drug stores, care homes, and hospitals; and handles and coordinates the purchase, sale, warehousing, and distribution of products for third parties. Its Retail segment operates 483 pharmacies, including 312 own pharmacies and 171 partner pharmacies under the Amavita and Sun Store brands in Switzerland. This segment also operates a chain of 55 own pharmacies in partnership under the Coop Vitality brand; MediService specialty pharmacy that offers medication for the treatment of patients in their own homes; and 160 Winconcept partner pharmacies. The company’s HealthCare Information segment provides master data systems for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products. This segment also maintains databases; offers management solutions under the Triamun brand name; TriaPharm total management software solution for pharmacies; TriaMed software for physicians; and TriaOne non-sector specific ERP solution for retail. Galenica Ltd. was founded in 1927 and is headquartered in Bern, Switzerland.

Founded in 1927

galenica ag-reg (G2A) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

galenica ag-reg (G2A) Key Developments

Galenica Eyes Acquisitions

Galenica Ltd. (SWX:GALN) is looking for acquisition opportunities. Etienne Jornod, Executive Chairman of the Board of Directors of Galenica, said, Galenica will take three to five year, possibly less; if we have good acquisition of good deals we will see.

Galenica Ltd. Reports Consolidated Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Year 2014

Galenica Ltd. reported consolidated earnings results for the first half of 2014. The consolidated net sales in the first half of 2014 totalled CHF 1,661.5 million (0.8%). EBIT was CHF 189 million compared to CHF 182.0 million (excluding one-time effects) a year ago. EBITDA was CHF 227.5 million compared to CHF 219.1 million (excluding one-time effects) a year ago. Net profit was CHF 149.6 million compared to CHF 138.6 million (excluding one-time effects) a year ago. Net profit attributable to shareholders of the company was CHF 134.7 million compared to CHF 126.9 million (excluding one-time effects) a year ago. The group's management has set itself the target of increasing group net profit on a comparable basis for 2014, both before and after deduction of minority interests, for the 19th consecutive year.

Galenica To List Vifor And Santé

Galenica Ltd. (SWX:GALN) is planning to list Santé and Vifor Pharma Ltd. "With this move, the Board of Directors of the Galenica Group is creating the best possible conditions for both the Vifor Pharma and Galenica Sante units to prepare to become listed, independent companies when the time is right," the Bern-based company said in a statement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
G2A:GR €715.54 EUR +1.89

G2A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for G2A.
View Industry Companies

Industry Analysis


Industry Average

Valuation G2A Industry Range
No financial data is available for G2A.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENICA AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at